Please login to the form below

Not currently logged in
Email:
Password:

Merck & Co expands board and adds new directors

Appoints Dr Paul Rothman and Pamela Craig

Merck & Co has appointed Dr Paul Rothman and Pamela Craig to two newly-created spaces on its board, with effect from next month, bringing its total members to 14.

Dr Rothman, who will serve as a member of Merck's research committee, is dean of the medical faculty and vice president for medicine at The Johns Hopkins University and chief executive officer of Johns Hopkins Medicine.

A rheumatologist and molecular immunologist, he joined Johns Hopkins in July 2012 after having served as dean of the Carver College of Medicine at the University of Iowa and leader of its clinical practice plan since 2008.

Meanwhile, Craig is a former chief financial officer of Accenture and will serve as a member of Merck's audit committee.

Craig, who retired from Accenture in 2013, spent 34 years at the consulting firm and is currently a senior advisor for advisory firm Teneo, is a member of the board for the tech firms Akamai Technologies and VMware and for Wal-Mart Stores.

Kenneth Frazier, Merck's chairman and chief executive officer, said: “We are pleased to welcome Pamela Craig and Dr Paul Rothman to the Merck board. Each brings a tremendous wealth of experience and expertise in their respective fields.

“We are confident that their contributions and insights will further strengthen the board.”

31st July 2015

From: Research, Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Fishawack Group of Companies

The Fishawack Group of Companies is one of the largest independent medical communications and medical marketing specialists, with teams in...

Latest intelligence

Enabling market access through outcomes-based pricing
Outcomes-based pricing is a potential solution to create a link between product price and real-world outcomes, while at the same time facilitating patient access to new and innovative medicines....
Five companies 20 for 2020
20 for 2020 – Five pharma companies to watch
As a new decade gets into gear, we take a look at five pharma companies that have a lot riding on 2020...
The growing clinical importance of patient-reported outcomes (PROs)
Traditionally, the success or otherwise of medical treatments has been assessed by mortality or clinical assessments of health. However, patient self-reports of health are increasingly seen as central to the...

Infographics